Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers.

Rothuizen LE, Buclin T, Spertini F, Trinchard I, Munafo A, Buchwalder PA, Ythier A, Biollaz J.

J Neuroimmunol. 1999 Sep 1;99(1):131-41.

PMID:
10496186
2.

Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.

Brod SA, Marshall GD Jr, Henninger EM, Sriram S, Khan M, Wolinsky JS.

Neurology. 1996 Jun;46(6):1633-8.

PMID:
8649562
3.

A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.

Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, Zhu Y, Crossman M, Nestorov I, Gronke RS, Baker DP, Rogge M, Subramanyam M, Davar G.

J Clin Pharmacol. 2012 Jun;52(6):798-808. doi: 10.1177/0091270011407068. Epub 2011 Jun 16. Erratum in: J Clin Pharmacol. 2012 Sep;52(9):NP4-5.

PMID:
21680782
4.

Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously.

Liberati AM, Garofani P, De Angelis V, Di Clemente F, Horisberger M, Cecchini M, Betti AR, Palmisano L, Astolfi S, Nastari A, et al.

J Interferon Res. 1994 Apr;14(2):61-9.

PMID:
8077767
5.

Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.

Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, Witt PL, Teitelbaum AP, Smalley RV, Borden EC.

J Natl Cancer Inst. 1989 Jul 19;81(14):1061-8.

PMID:
2472488
6.
7.

A phase I study of recombinant interferon-beta in patients with advanced malignant disease.

Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz M.

Clin Cancer Res. 1999 Dec;5(12):3990-8.

9.

Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.

Tilg H, Vogel W, Tratkiewicz J, Aulitzky WE, Herold M, Gruber M, Geissler D, Umlauft F, Judmaier G, Schwulera U, et al.

J Hepatol. 1993 Sep;19(2):259-67.

PMID:
8301059
10.

Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-╬▓ 1a treated multiple sclerosis patients.

Christophi GP, Christophi JA, Gruber RC, Mihai C, Mejico LJ, Massa PT, Jubelt B.

J Neurol Sci. 2011 Aug 15;307(1-2):41-5. doi: 10.1016/j.jns.2011.05.024. Epub 2011 Jun 11.

11.

Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.

Schiller JH, Storer B, Witt PL, Nelson B, Brown RR, Horisberger M, Grossberg S, Borden EC.

Cancer Res. 1990 Aug 1;50(15):4588-94.

12.

Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.

Hughes RA, Gorson KC, Cros D, Griffin J, Pollard J, Vallat JM, Maurer SL, Riester K, Davar G, Dawson K, Sandrock A; Avonex CIDP Study Group..

Neurology. 2010 Feb 23;74(8):651-7. doi: 10.1212/WNL.0b013e3181d1a862.

PMID:
20177118
13.

Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study.

Pena Rossi C, Hanauer SB, Tomasevic R, Hunter JO, Shafran I, Graffner H.

BMC Gastroenterol. 2009 Mar 20;9:22. doi: 10.1186/1471-230X-9-22.

14.

Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response.

Graber JJ, Ford D, Zhan M, Francis G, Panitch H, Dhib-Jalbut S.

J Neuroimmunol. 2007 Apr;185(1-2):168-74. Epub 2007 Feb 27.

16.

Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.

Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A.

J Interferon Cytokine Res. 1996 Oct;16(10):759-64.

PMID:
8910759
17.

Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.

St├╝rzebecher S, Maibauer R, Heuner A, Beckmann K, Aufdembrinke B.

J Interferon Cytokine Res. 1999 Nov;19(11):1257-64.

PMID:
10574618
18.

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.

Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L.

Lancet Neurol. 2012 Jan;11(1):33-41. doi: 10.1016/S1474-4422(11)70262-9. Epub 2011 Dec 4. Erratum in: Lancet Neurol. 2012 Feb;11(2):125.

PMID:
22146409
19.

Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta.

Witt PL, Storer BE, Bryan GT, Brown RR, Flashner M, Larocca AT, Colby CB, Borden EC.

J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):191-200.

PMID:
8471593
20.

Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.

Witt PL, Ritch PS, Reding D, McAuliffe TL, Westrick L, Grossberg SE, Borden EC.

Cancer Res. 1993 Nov 1;53(21):5176-80.

Supplemental Content

Support Center